Literature DB >> 32713788

Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS.

Christoph F Dietrich1, Christian Pállson Nolsøe2, Richard G Barr3, Annalisa Berzigotti4, Peter N Burns5, Vito Cantisani6, Maria Cristina Chammas7, Nitin Chaubal8, Byung Ihn Choi9, Dirk-André Clevert10, Xinwu Cui11, Yi Dong12, Mirko D'Onofrio13, J Brian Fowlkes14, Odd Helge Gilja15, Pintong Huang16, Andre Ignee17, Christian Jenssen18, Yuko Kono19, Masatoshi Kudo20, Nathalie Lassau21, Won Jae Lee22, Jae Young Lee23, Ping Liang24, Adrian Lim25, Andrej Lyshchik26, Maria Franca Meloni27, Jean Michel Correas28, Yasunori Minami29, Fuminori Moriyasu30, Carlos Nicolau31, Fabio Piscaglia32, Adrian Saftoiu33, Paul S Sidhu34, Ioan Sporea35, Guido Torzilli36, Xiaoyan Xie37, Rongqin Zheng38.   

Abstract

The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology. The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as, previously, the differences in the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including U.S. Food and Drug Administration approval and the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCAs) and are intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.
Copyright © 2020 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contrast-enhanced ultrasound; Guideline; Liver; World Federation for Ultrasound in Medicine and Biology

Year:  2020        PMID: 32713788     DOI: 10.1016/j.ultrasmedbio.2020.04.030

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  45 in total

1.  Early hemodynamics of hepatocellular carcinoma using contrast-enhanced ultrasound with Sonazoid: focus on the pure arterial and early portal phases.

Authors:  Akiko Saito; Masakazu Yamamoto; Satoshi Katagiri; Shingo Yamashita; Masayuki Nakano; Toshio Morizane
Journal:  Glob Health Med       Date:  2020-10-31

2.  Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study.

Authors:  Alina Makoyeva; Tae Kyoung Kim; Hyun-Jung Jang; Alejandra Medellin; Stephanie R Wilson
Journal:  Radiol Imaging Cancer       Date:  2020-03-27

3.  Contrast-enhanced ultrasound (CEUS) in patients with metastasis-like hepatic alveolar echinococcosis: a cohort study.

Authors:  Melissa Schweizer; Julian Schmidberger; Patrycja Schlingeloff; Wolfgang Kratzer
Journal:  J Ultrasound       Date:  2022-05-21

Review 4.  [Standardized contrast-enhanced ultrasound (CEUS) in clinical acute and emergency medicine and critical care (CEUS Acute) : Consensus statement of DGIIN, DIVI, DGINA, DGAI, DGK, ÖGUM, SGUM and DEGUM].

Authors:  Guido Michels; Rudolf Horn; Andreas Helfen; Andreas Hagendorff; Christian Jung; Beatrice Hoffmann; Natalie Jaspers; Horst Kinkel; Clemens-Alexander Greim; Fabian Knebel; Johann Bauersachs; Hans-Jörg Busch; Daniel Kiefl; Alexander O Spiel; Gernot Marx; Christoph F Dietrich
Journal:  Med Klin Intensivmed Notfmed       Date:  2022-02       Impact factor: 0.840

Review 5.  Recent advances in ultrasound in the diagnosis and evaluation of the activity of hepatic alveolar echinococcosis.

Authors:  Cai-Rang Yangdan; Cong Wang; Ling-Qiang Zhang; Bin Ren; Hai-Ning Fan; Ming-De Lu
Journal:  Parasitol Res       Date:  2021-08-09       Impact factor: 2.289

6.  Can Risk Stratification Based on Ultrasound Elastography of Background Liver Assist CEUS LI-RADS in the Diagnosis of HCC?

Authors:  Jiawu Li; Wenwu Ling; Shuang Chen; Lulu Yang; Lin Ma; Qiang Lu; Yan Luo
Journal:  Front Oncol       Date:  2021-04-30       Impact factor: 6.244

7.  Contrast-Enhanced Ultrasound Imaging of Uterine Disorders: A Systematic Review.

Authors:  Barbara Stoelinga; Lynda Juffermans; Anniek Dooper; Marleen de Lange; Wouter Hehenkamp; Thierry Van den Bosch; Judith Huirne
Journal:  Ultrason Imaging       Date:  2021-05-26       Impact factor: 1.578

8.  Parametric Imaging of Contrast-Enhanced Ultrasound (CEUS) for the Evaluation of Acute Gastrointestinal Graft-Versus-Host Disease.

Authors:  Antonia-Maria Pausch; Sylvia Kammerer; Florian Weber; Wolfgang Herr; Christian Stroszczynski; Ernst Holler; Matthias Edinger; Daniel Wolff; Daniela Weber; Ernst-Michael Jung; Tobias Wertheimer
Journal:  Cells       Date:  2021-05-03       Impact factor: 6.600

Review 9.  Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Andrea Belli; Carmen Cutolo; Silvia Pradella; Giulia Grazzini; Michelearcangelo La Porta; Maria Chiara Brunese; Federica De Muzio; Alessandro Ottaiano; Antonio Avallone; Francesco Izzo; Antonella Petrillo
Journal:  Infect Agent Cancer       Date:  2021-07-19       Impact factor: 2.965

10.  A Nomogram Based on Combining Clinical Features and Contrast Enhanced Ultrasound LI-RADS Improves Prediction of Microvascular Invasion in Hepatocellular Carcinoma.

Authors:  Hang Zhou; Jiawei Sun; Tao Jiang; Jiaqi Wu; Qunying Li; Chao Zhang; Ying Zhang; Jing Cao; Yu Sun; Yifan Jiang; Yajing Liu; Xianli Zhou; Pintong Huang
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.